Equillium files Metacrine financials and pro forma statements for pending merger

Equillium, Inc.

Metacrine 2021 net loss $62.2M; accumulated deficit $182.95M as of Dec 31, 2021.
Audited financials for 2021 and 2020, plus unaudited interim statements through June 30, 2022 filed.
Unaudited pro forma combined balance sheet as of June 30, 2022 reflects the acquisition.
Updated risk factor disclosure filed as Exhibit 99.3 to supplement prior filings.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.